Nimotuzumab added to standard treatment after glioblastoma surgery
Original title: Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the treatment has been tried in people but is still being studied.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called nimotuzumab alongside the usual treatment given after brain tumor surgery.
Who this trial is for. This trial is for adults with high grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that tests positive for EGFR, who still have tumor showing on scans after surgery. Everyone in the trial gets nimotuzumab along with the standard Stupp treatment given after glioma surgery.
Where it stands. There are no results yet. The trial is looking at what happens when nimotuzumab is added to the standard Stupp treatment after surgery. Everyone in this study gets the same treatment, so there is no comparison group. The source does not report any findings.
What this means, and what it doesn't
What it could mean: For now, this only means the idea is being tested in people. If you had glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary surgery, still have tumor on your scans, and your tumor is EGFR positive, you could ask your care team whether a trial like this is worth looking into. They can explain how it might fit your situation.
What it doesn't mean: This does not mean nimotuzumab is a proven treatment. A trial is a test. We do not know yet if adding this drug helps. Joining a trial is not a guarantee that you will do better, and it is not a promise of a cure. It also does not mean you can join. The trial team decides who is a fit.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.